menu
    • menu
    [{"orgOrder":0,"company":"Genome & Company","sponsor":"Scioto Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Genome & Company","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Genome & Company \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Genome & Company \/ Genome & Company"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"GENA-104","moa":"CNTN4","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genome & Company \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Ellipses Pharma"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genome & Company \/ Genome & Company","highestDevelopmentStatusID":"15","companyTruncated":"Genome & Company \/ Genome & Company"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"GEN-001","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"GEN-001","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"Genome & Company \/ Merck Group"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck Group | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"GEN-001","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Merck Group | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Merck Group | Pfizer Inc"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Undisclosed"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Genome & Company \/ Merck & Co"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Undisclosed"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Undisclosed"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Probiotic","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Genome & Company","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Genome & Company"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genome & Company","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Genome & Company \/ Genome & Company","highestDevelopmentStatusID":"4","companyTruncated":"Genome & Company \/ Genome & Company"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GENA-104A16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genome & Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Undisclosed"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genome & Company \/ Debiopharm","highestDevelopmentStatusID":"3","companyTruncated":"Genome & Company \/ Debiopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Genome & Company

    Menu

    Genome & Company

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GENA-104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ellipses Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ellipses In-Licences GENA-104 A Novel Immuno-Oncology Agent

                            Details : Under the licensing agreement with Genome, Ellipses will take responsibility for all future clinical development of EP0089 (GENA-104) for the treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            February 11, 2025

                            Lead Product(s) : GENA-104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ellipses Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Genomma Lab Announces Strategic Bolt-On Acquisition of Four Brands

                            Details : Genomma acquired the IBU 400 and Treg brands which enables Genomma to enter the ibuprofen segment, the second largest analgesics category, further strengthening the Company's position.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : Ibuprofen

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Debiopharm And Genome & Company Partner On Novel Oncology ADC Family

                            Details : Debiopharm is granted exclusive global rights to use Genome & Company’s antibodies to develop potential first-in-class ADCs integrating Debiopharm’s Multilink™ technology to treat cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Debiopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GENA-104A16

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

                            Details : GENA-104A16 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 01, 2024

                            Lead Product(s) : GENA-104A16

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

                            Details : GEN-001 is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Biliary Tract Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 21, 2023

                            Lead Product(s) : GEN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-001,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results from Interim Analysis of 'GEN-001' Plus Avelumab (Bavencio®) Phase II Trial

                            Details : GEN-001 is being developed as an orally administered microbiome therapeutic with Lactococcus lactis, a single strain bacteria isolated from a healthy human. Its anticancer efficacy was proven by activating immune activity of cancer cells.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            May 19, 2023

                            Lead Product(s) : GEN-001,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

                            Details : GEN-001 is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stomach Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : GEN-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genome and Company Announces Clinical Trial Collaboration with MSD to Evaluate 'GEN-001' in Combination of KEY...

                            Details : Upon the execution of the agreement, Genome will conduct a phase 2 clinical trial to evaluate the safety and efficacy of its immuno-oncology microbiome therapeutic, GEN-001, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with bili...

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            March 03, 2022

                            Lead Product(s) : GEN-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Oramed Pharmaceuticals

                            Deal Size : $20.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercia...

                            Details : Genomma Lab is expected to contribute resources to the joint venture’s oral COVID-19 vaccine development, as well as clinical, regulatory, and commercial activities in Mexico.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Oramed Pharmaceuticals

                            Deal Size : $20.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Genome & Company

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-001,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genome and Company Ink 2nd Clinical Trial Collaboration and Supply Agreement with Merck KGA and Pfizer for Imm...

                            Details : The collaboration follows in just a year after signing the first agreement with Merck KGaA, Darmstadt, Germany and Pfizer in December 2019 to conduct the first combination clinical trial of avelumab (BAVENCIO®) and GEN-001.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Undisclosed

                            March 09, 2021

                            Lead Product(s) : GEN-001,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth